Trials / Completed
CompletedNCT05566639
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 22,502 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | mRNA-1010 | Sterile liquid for injection |
| BIOLOGICAL | Fluarix Quadrivalent | Sterile suspension for injection. |
Timeline
- Start date
- 2022-09-14
- Primary completion
- 2024-01-05
- Completion
- 2024-01-05
- First posted
- 2022-10-04
- Last updated
- 2025-01-16
- Results posted
- 2025-01-16
Locations
233 sites across 11 countries: United States, Bulgaria, Canada, Denmark, Estonia, Germany, Netherlands, Poland, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05566639. Inclusion in this directory is not an endorsement.